While I too agree with this line of thinking, which is exactly why I kept saying the issue is directed at that "particular" GH and stated it's "debatable", I think it's wise that you see the flip side of this agrument. The manufacturers of Jintropin, GeneScience claim otherwise:
**broken link removed**
What’s the consequence of using low quality cheap hGH brand or 192 amino acid hGH ?
"Most low quality cheap hGH brands does contain hGH, but they also contain lots of E.coli host protein contamination. When injected (or when you injected 192 amino acid hGH), you would feel the hGH function, but in the meantime, your body will quickly generate antibodies to hGH. In a few months, your body’s hGH will stop functioning, and any new injection of hGH will be useless . Therefore it is key to always stick to the highest quality hGH--Jintropin™. Jintropin™ is the only hGH in China that causes minimum antibody formation, therefore, it is the best for long term use."
In my opinion, it's best NOT to test out their claims. The risk far out ways the possible reward. The smart thing either way is to simply toss away the junky GH and begin using another.
Here is a portion of the insert from Saizen:
ADVERSE REACTIONS
Growth Hormone Defi cient Pediatric Patients
As with all protein pharmaceuticals, a small percentage of patients may develop antibodies to the
protein. Anti-growth hormone (GH) antibody capacities below 2 mg/L have not been associated with
growth attenuation. In some cases when binding capacity exceeds 2 mg/L, growth attenuation has been
described. In clinical studies with Saizen® involving 280 patients (204 naive and 76 transfer patients),
one patient at 6 months of therapy developed anti-GH antibodies with binding capacities exceeding
2 mg/L. Despite the high binding capacity, these antibodies were not growth attenuating. The patient
was subsequently shown to have a hGH-N gene defect. Thus, genetic analysis should be undertaken
in any patient in whom anti-GH antibodies with high binding capacities occur. No antibodies against
proteins of the host cells were detected in the sera of patients treated up to fi ve years.
Any patient with well-documented growth hormone defi ciency who fails to respond to therapy should
be tested for antibodies to human growth hormone and for thyroid status.
In clinical studies in which Saizen® was administered to growth hormone defi cient children, the
following events were infrequently seen: local reactions at the injection site (such as pain, numbness,
redness and swelling), hypothyroidism, hypoglycemia, seizures, exacerbation of preexisting psoriasis
and disturbances in fl uid balance.